Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

40,714 52,637 69,532 448,397

Stock based

compensation 539,156 403,550 64,104 4,704,805

Other non-cash

items - - 224,508 1,383,537

Net change in

non-cash working

capital 530,300 811,922 584,766 2,435,221

-------------------------------------------------------------------------

Cash used in

operating

activities (13,569,594) (12,155,372) (11,052,462) (66,551,036)

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Intellectual

property (852,498) (842,610) (1,033,035) (6,351,778)

Capital assets (92,221) (35,837) (61,309) (715,569)

Purchase of

short-term

investments (949,496) (1,035,427) (22,195,253) (49,068,963)

Redemption of

short-term

investments 6,573,000 13,808,000 6,656,746 30,151,746

Investment in

BCY LifeSciences

Inc. - - 7,965 464,602

Investment in

Transition

Therapeutics

Inc. - - - 2,532,343

-------------------------------------------------------------------------

Cash provided by

(used in)

investing

activities 4,678,785 11,894,126 (16,624,886) (22,987,619)

-------------------------------------------------------------------------

FINANCING ACTIVITIES

Proceeds from

exercise of

stock options

and warrants 51,000 241,400 3,384,787 15,259,468

Proceeds from

private

placements - - 15,395,402 38,137,385

Proceeds from

public

offerings 12,063,394
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 Slone ... Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, reported ... positions at the director level and above from July ... to stay on top of rapid breakthroughs in diagnostics, ... many diagnostic companies have been forced to fold, consolidate, ...
(Date:9/30/2014)... German . , The ... a semiconductor layer. Quantum dots are small structures that spontaneously ... short laser pulse is fired at the photonic crystal, its ... change in the electromagnetic field around it. This change can ... the dot. As soon as the refractive index recovers its ...
(Date:9/30/2014)... , Sept. 30, 2014 Report Details ... with highest potential revenues Do you want to ... gives you revenue predictions for those biological drugs ... therapies you find financial data, R&D trends, opportunities ... get sales forecasts to 2024 at overall world ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
Breaking Biology Technology:Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Jay Bigelow, President of MicroMass,Communications, Inc., a ... by PharmaVOICE magazine as one of the 100 ... industry., The honor was announced in the ... top leaders in all areas of the pharmaceutical,industry. ...
... deCODE genetics,Inc. (Nasdaq: DCGN ) today announced ... in a press release to be issued on Wednesday, ... York. The company will host a live,webcast of its ... on Thursday, August 7, at 8am EDT/12 noon GMT/1pm,British ...
... (Amex: NBS ),has announced that it has broadened ... development agreement with Stem Collect LLC,NeoStem has added the ... The Los Angeles area is a significant healthcare market ... physician practices,and hospitals offering a dynamic and diverse population ...
Cached Biology Technology:MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences 2MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences 3deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2008 Financial Results 2NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist 2NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist 3
(Date:10/1/2014)... that thrive in the deserts, rainforests, prairies and forests ... New York City,s Central Park, according to a surprising ... University of Colorado Boulder. , The research team ... 843 acres and discovered a stunning diversity of below-ground ... , Only 8.5 percent to 16.2 percent of ...
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2
... disease researchers at The Miriam Hospital and Brown Medical School ... is also safe when applied as a vaginal microbicide gel. ... and other sexually transmitted diseases and may be formulated as ... of this study may change the way the research community ...
... A common virus that causes meningitis and heart inflammation ... then exploits biological signals to infect human cells. Broadening ... describes elaborate methods that the virus has evolved to ... explain how group B coxsackieviruses infect cells," said Jeffrey ...
... with multiple partners almost quadruples a teenager's risk of ... BMJ today. , Meningococcal disease is a life threatening ... in adolescence. , The incidence and fatality rate ... dramatically during the 1990s, but little is known about ...
Cached Biology News:Anti-HIV drug has potential to prevent transmission in women 2Anti-HIV drug has potential to prevent transmission in women 3Research details how a virus hijacks cell signals to cause infection 2
...
...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: